Denosumab: a new option in the treatment of bone metastases from urological cancers

References

• RoodmanGDMechanisms of bone metastasisN Engl J Med2004350161655166415084698
   PubMed Web of Science ®Google Scholar
• OnishiTHayashiNTheriaultRLHortobagyiGNUenoNTFuture directions of bone-targeted therapy for metastatic breast cancerNat Rev Clin Oncol201071164165120808302
   PubMed Web of Science ®Google Scholar
• MorganSCParkerCCLocal treatment of metastatic cancer – killing the seed or disturbing the soil?Nat Rev Clin Oncol20118850450621647193
   PubMed Web of Science ®Google Scholar
• ColemanREBisphosphonates: clinical experienceOncologist20049Suppl 4142715459426
   PubMed Web of Science ®Google Scholar
• SaadFGleasonDMMurrayRTZoledronic Acid Prostate Cancer Study GroupA randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinomaJ Natl Cancer Inst200294191458146812359855
   PubMed Web of Science ®Google Scholar
• RosenLSGordonDTchekmedyianSZoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial – the Zoledronic Acid Lung Cancer and Other Solid Tumors Study GroupJ Clin Oncol200321163150315712915606
   PubMed Web of Science ®Google Scholar
• LiptonAColombo-BerraABukowskiRMRosenLZhengMUrbanowitzGSkeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acidClin Cancer Res20041018 Pt 26397S6403S15448038
   PubMed Web of Science ®Google Scholar
• KohnoNAogiKMinamiHZoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trialJ Clin Oncol200523153314332115738536
   PubMed Web of Science ®Google Scholar
• WittrantYThéoleyreSChipoyCRANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysisBiochim Biophys Acta200417042495715363860
   PubMed Web of Science ®Google Scholar
• HofbauerLCSchoppetMClinical implications of the osteoprotegerin/ RANKL/RANK system for bone and vascular diseasesJAMA2004292449049515280347
   PubMed Web of Science ®Google Scholar
• BodyJJFaconTColemanREA study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancerClin Cancer Res20061241221122816489077
   PubMed Web of Science ®Google Scholar
• HenryDHCostaLGoldwasserFRandomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myelomaJ Clin Oncol20112991125113221343556
   PubMed Web of Science ®Google Scholar
• SrinivasanRLinehanWMTreatment of advanced renal cell carcinomaKavoussiLRNovickACPartinAWPetersCAWeinAJCampbell-Walsh Urology10th edNew York, NYSaunders201114751491
   Google Scholar
• LjungbergBHanburyDCKuczykMAEuropean Association of Urology Guideline Group for renal cell carcinomaRenal cell carcinoma guidelineEur Urol20075161502151017408850
   PubMed Web of Science ®Google Scholar
• YuasaTUrakamiSYamamotoSTreatment outcome and prognostic factors of the patients with renal cell cancer bone metastasisClin Exp Metastasis201128440541121365325
   PubMed Web of Science ®Google Scholar
• LiptonAManagement of Bone Metastasis in patients with Renal Cell Carcinoma and Other Malignancies of the Genitourinary TractKantoffPSaadFSmithMRManagement of Skeletal Complications of Prostate Cancer and Other Genitourinary MalignanciesPhiladelphia, PAFA Davis Co2004207234
   Google Scholar
• ZekriJAhmedNColemanREHancockBWThe skeletal metastatic complications of renal cell carcinomaInt J Oncol200119237938211445855
   PubMed Web of Science ®Google Scholar
• NaitoSYamamotoNTakayamaTPrognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patientsEur Urol20105731732519136199
   PubMed Web of Science ®Google Scholar
• KuczykMAAnastasiadisAGZimmermannRMerseburgerASCorvinSStenziACurrent aspects of the surgical management of organ-confined, metastatic, and recurrent renal cell cancerBJU Int2005965721727 quiz i–ii.16144527
   PubMed Web of Science ®Google Scholar
• ToyodaYShinoharaNHarabayashiTSurvival and prognostic classification of patients with metastatic renal cell carcinoma of boneEur Urol200752116316817098353
   PubMed Web of Science ®Google Scholar
• MotzerRJBacikJMurphyBARussoPMazumdarMInterferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinomaJ Clin Oncol200220128929611773181
   PubMed Web of Science ®Google Scholar
• SiegelRNaishadhamDJemalACancer statistics, 2012CA Cancer J Clin2012621102922237781
   PubMed Web of Science ®Google Scholar
• LernerSPSternbergCNManagement of metastatic and invasive bladder cancerKavoussiLRNovickACPartinAWPetersCAWeinAJCampbell-Walsh Urology10th edNew York, NYSaunders201123552374
   Google Scholar
• GeeJSabichiALGrossmanHBChemoprevention of superficial bladder cancerCrit Rev Oncol Hematol200243327728612270783
   PubMed Web of Science ®Google Scholar
• StenzlACowanNCDe SantisMEuropean Association of Urology (EAU)Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelinesEur Urol20115961009101821454009
   PubMed Web of Science ®Google Scholar
• DreicerRLocally advanced and metastatic bladder cancerCurr Treat Options Oncol20012543143612057106
   PubMedGoogle Scholar
• BabaianRJJohnsonDELlamasLAyalaAGMetastases from transitional cell carcinoma of urinary bladderUrology19801621421447404907
   PubMed Web of Science ®Google Scholar
• HussainSAJamesNDThe systemic treatment of advanced and metastatic bladder cancerLancet Oncol20034848949712901963
   PubMed Web of Science ®Google Scholar
• BellmuntJAlbanellJPaz-AresLSpanish Oncology Genitourinary GroupPretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabineCancer200295475175712209718
   PubMed Web of Science ®Google Scholar
• TsukamotoTYoneseJOhkuboYFukuiIPhase I/II study of a combined gemcitabine, etoposide, and cisplatin chemotherapy regimen for metastatic urothelial carcinomaCancer2006106112363236816649219
   PubMed Web of Science ®Google Scholar
• NelsonJBHormonal therapy of prostate cancerKavoussiLRNovickACPartinAWPetersCAWeinAJCampbell-Walsh Urology10th edNew York, NYSaunders201129342953
   Google Scholar
• JohanssonJEAndrénOAnderssonSONatural history of early, localized prostate cancerJAMA2004291222713271915187052
   PubMed Web of Science ®Google Scholar
• ScherHIHalabiSTannockIProstate Cancer Clinical Trials Working GroupDesign and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working GroupJ Clin Oncol20082671148115918309951
   PubMed Web of Science ®Google Scholar
• PetrylakDPTangenCMHussainMHDocetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancerN Engl J Med2004351151513152015470214
   PubMed Web of Science ®Google Scholar
• TannockIFde WitRBerryWRTAX 327 InvestigatorsDocetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancerN Engl J Med2004351151502151215470213
   PubMed Web of Science ®Google Scholar
• YuasaTKimuraSAshiharaEHabuchiTMaekawaTZoledronic acid – a multiplicity of anti-cancer actionCurr Med Chem200714202126213517691952
   PubMed Web of Science ®Google Scholar
• KimuraSKurodaJSegawaHAntiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anti-cancer drugs in leukemic cell linesInt J Hematol2004791374314979476
   PubMed Web of Science ®Google Scholar
• MatsumotoSKimuraSSegawaSEfficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell linesLung Cancer200547313915603852
   PubMed Web of Science ®Google Scholar
• Neville-WebbeHLEvansCAColemanREHolenIMechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitroTumour Biol20062729210316582586
   PubMedGoogle Scholar
• JagdevSPColemanREShipmanCMRostami-HACroucherPIThe bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxelBr J Cancer20018481126113411308265
   PubMed Web of Science ®Google Scholar
• SmithMROsteoporosis and obesity in men receiving hormone therapy for prostate cancerJ Urol20041725 Pt 2S52S5615535444
   PubMedGoogle Scholar
• WangWYuasaTTsuchiyaNBone mineral density in Japanese prostate cancer patients under androgen-deprivation therapyEndocr Relat Cancer200815494395218667685
   PubMed Web of Science ®Google Scholar
• YuasaTMaitaSTsuchiyaNRelationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patientsUrology20107551131113720163839
   PubMed Web of Science ®Google Scholar
• HugginsCHodgesVCStudies on prostate cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostateCancer Res19411293297
   Google Scholar
• CooperbergMRGrossfeldGDLubeckDPCarrollPRNational practice patterns and time trends in androgen ablation for localized prostate cancerJ Natl Cancer Inst2003951398198912837834
   PubMedGoogle Scholar
• SharifiNGulleyJLDahutWLAndrogen deprivation therapy for prostate cancerJAMA2005294223824416014598
   PubMed Web of Science ®Google Scholar
• HiganoCSSide effects of androgen deprivation therapy: monitoring and minimizing toxicityUrology2003612 Suppl 1323812667885
   PubMed Web of Science ®Google Scholar
• ShahinianVBKuoYFFreemanJLGoodwinJSRisk of fracture after androgen deprivation for prostate cancerN Engl J Med2005352215416415647578
   PubMed Web of Science ®Google Scholar
• GreenspanSLCoatesPSereikaSMNelsonJBTrumpDLResnickNMBone loss after initiation of androgen deprivation therapy in patients with prostate cancerJ Clin Endocrinol Metab200590126410641716189261
   PubMed Web of Science ®Google Scholar
• BruderJMMaJZBaslerJWWelchMDPrevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapyUrology200667115215516413352
   PubMed Web of Science ®Google Scholar
• MoroteJMorinJPOrsolaAPrevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancerUrology200769350050417382153
   PubMed Web of Science ®Google Scholar
• MoroteJOrsolaAAbascalJMBone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppressionJ Urol200717551679168316600728
   PubMed Web of Science ®Google Scholar
• OefeleinMGRicchiutiVSConradPWClinical predictors of androgen-independent prostate cancer and survival in the prostate-specific antigen eraUrology200260112012412100936
   PubMed Web of Science ®Google Scholar
• MikamiSKatsubeKOyaMIncreased RANKL expression is related to tumour migration and metastasis of renal cell carcinomasJ Pathol2009218453053919455604
   PubMed Web of Science ®Google Scholar
• ChenGSircarKAprikianAPottiAGoltzmanDRabbaniSAExpression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulationCancer2006107228929816752412
   PubMed Web of Science ®Google Scholar
• NaritaNYuasaTTsuchiyaNA genetic polymorphism of the osteoprotegerin gene is associated with an increased risk of advanced prostate cancerBMC Cancer2008822418684318
   PubMed Web of Science ®Google Scholar
• FleischHDevelopment of bisphosphonatesBreast Cancer Res200241303411879557
   PubMed Web of Science ®Google Scholar
• ZaghloulMSBoutrusREl-HossienyHKaderYAEl-AttarINazmyMA prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancerInt J Clin Oncol201015438238920354750
   PubMed Web of Science ®Google Scholar
• YuasaTNogawaMKimuraSA third-generation bisphosphonate, minodronic acid (YM529), augments the interferon αβ-mediated inhibition of renal cell cancer cell growth both in vitro and in vivoClin Cancer Res2005112 Pt 185385915701876
   PubMed Web of Science ®Google Scholar
• SatoKYuasaTNogawaMA third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivoBr J Cancer200695101354136117043684
   PubMed Web of Science ®Google Scholar
• MaitaSYuasaTTsuchiyaNAntitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast functionInt J Cancer2012130367768421387300
   PubMed Web of Science ®Google Scholar
• JonesDHNakashimaTSanchezOHRegulation of cancer cell migration and bone metastasis by RANKLNature2006440708469269616572175
   PubMed Web of Science ®Google Scholar
• Gonzalez-SuarezEJacobAPJonesJRANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesisNature2010468732010310720881963
   PubMed Web of Science ®Google Scholar
• MillerRERoudierMJonesJArmstrongACanonJDougallWCRANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasisMol Cancer Ther2008772160216918606716
   PubMed Web of Science ®Google Scholar
• SmithMREgerdieBHernández TorizNDenosumab HALT Prostate Cancer Study GroupDenosumab in men receiving androgen-deprivation therapy for prostate cancerN Engl J Med2009361874575519671656
   PubMed Web of Science ®Google Scholar
• FizaziKCarducciMSmithMDenosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyLancet2011377976881382221353695
   PubMed Web of Science ®Google Scholar
• SmithMRSaadFColemanRDenosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trialLancet20123799810394622093187
   PubMed Web of Science ®Google Scholar